Vir Biotechnology, Inc. (VIR) Profit Margins
Over the twelve months to 2026-06-30, Vir Biotechnology, Inc. (VIR) had operating margin -92.4%, net margin -83.0%, free cash flow margin -67.1%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VIRVir Biotechnology, Inc.Follow VIR — free
—
Price chart with a free account
- Market cap
- 1.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | 94.0% | 90.9% | 96.8% | 98.9% | 100.0% | — | |
| Operating margin | -2199.7% | -388.9% | 38.4% | 51.6% | -794.0% | -791.3% | -699.2% | -92.4% | |
| Net margin | -2159.0% | -391.1% | 48.3% | 31.9% | -713.7% | -703.4% | -638.9% | -83.0% | |
| FCF margin | -1712.7% | -258.6% | -6.3% | 98.7% | -928.7% | -611.4% | -578.5% | -67.1% |
USD billions · SEC XBRL
Vir Biotechnology, Inc. — questions
- What is Vir Biotechnology, Inc.'s operating margin?
- -92.4% over the twelve months to 2026-06-30.
- What is Vir Biotechnology, Inc.'s net profit margin?
- -83.0% over the twelve months to 2026-06-30.
Every figure on this page comes from Vir Biotechnology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.